A Phase 3 interventional study of Evolocumab in Familial Hypercholesterolemia, sponsored by Amgen. Completed at 46 sites in 23 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy — 2 open to participants now, 3 under way, 1 of them phase 3. Homozygous Familial Hypercholesterolemia · Italy.
Among the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2016, is one of 8 in phase 3, and was the 7th registered.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
Browse Homozygous Familial Hypercholesterolemia studies →2 of the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy are open now. Recruiting first, the newest first:
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) · Sites in Italy, France, Netherlands and 1 more country
Ages 12+
Novartis Pharmaceuticals · Sites in Italy, United States, Argentina and 23 more countries
Ages 2–100
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 10
First in 2007; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Median enrollment 62 across the 12 interventional studies, 73 across the 3 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 15 have an industry lead sponsor. The 8 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 3 studies filed under Homozygous Familial Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
1 of the studies in Homozygous Familial Hypercholesterolemia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07447648Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Homozygous Familial Hypercholesterolemia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.
68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.
This study's enrollment of 163 is above the median of 21 across 51 interventional studies indexed under Homozygous Familial Hypercholesterolemia.
Browse Homozygous Familial Hypercholesterolemia studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Homozygous Familial Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hyperlipoproteinemia Type II. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Heterozygous Familial Hypercholesterolemia (HeFH):
-Completed Study 20120123 (NCT02392559) while still on assigned product and did not experience a treatment-related serious adverse event
Homozygous Familial Hypercholesterolemia (HoFH):
Exclusion Criteria:
-Currently receiving treatment in another device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s); except Study 20120123
HoFH:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 420 mg evolocumab administered by subcutaneous injection every 4 weeks (QM) for up to 80 weeks.
Biological: Evolocumab
Administered by subcutaneous injection
Also known as: Repatha®, AMG 145
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event is defined as any untoward medical occurrence in a clinical trial participant, not necessarily having a causal relationship with study treatment. A serious AE is as an AE that met at least 1 of the following criteria: * fatal; * life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. AEs were graded for severity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death related to AE.
Time frame: From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.
Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HeFH Participants
For HeFH participants baseline was defined as the baseline value of the parent study 20120123.
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HoFH Participants
For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Non-HDL-C in HeFH Participants
For HeFH participants baseline was defined as the baseline value of the parent study 20120123.
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Non-HDL-C in HoFH Participants
For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Apolipoprotein B in HeFH Participants
For HeFH participants baseline was defined as the baseline value in the parent study 20120123.
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Apolipoprotein B in HoFH Participants
For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HeFH Participants
For HeFH participants baseline was defined as the baseline value in the parent study 20120123.
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HoFH Participants
For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Apolipoprotein B / Apolipoprotein A1 Ratio in HeFH Participants
For HeFH participants baseline was defined as the baseline value in the parent study 20120123.
Time frame: Baseline and week 80
Percent Change From Baseline to Week 80 in Apolipoprotein B/Apolipoprotein A1 Ratio in HoFH Participants
For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Change From Baseline to Week 80 in LDL-C in HeFH Participants
For HeFH participants baseline was defined as the baseline value of the parent study 20120123.
Time frame: Baseline and week 80
Change From Baseline to Week 80 in LDL-C in HoFH Participants
For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Change From Baseline to Week 80 in Estradiol Levels
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Change From Baseline to Week 80 in Testosterone Levels
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Change From Baseline to Week 80 in Follicle Stimulating Hormone (FSH) Levels
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Change From Baseline to Week 80 in Luteinizing Hormone (LH) Levels
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Change From Baseline to Week 80 in Adenocorticotropic Hormone (ACTH) Levels
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Change From Baseline to Week 80 in Dehydroepiandrosterone Sulfate (DHEA-S) Levels
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Change From Baseline to Week 80 in Cortisol Levels
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
Time frame: Baseline and week 80
Number of Participants With Liver Function Test Abnormalities at Week 80
Liver function tests included alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels and total bilirubin levels.
Time frame: Week 80
Number of Participants With Abnormalities in Levels of Creatine Kinase (CK) at Week 80
The number of participants with levels of creatine kinase greater than 5 times the upper limit of normal (ULN) and greater than 10 times the ULN, measured by the central laboratory.
Time frame: Week 80
Change From Baseline to Week 80 in Carotid Intima-media Thickness (cIMT)
Carotid intima-media thickness measures the thickness of the intima and media, the inner two layers of the carotid artery, and is used to determine the extent of plaque buildup in the walls of the arteries (atherosclerosis) supplying blood to the head. CIMT was measured by ultrasonography and analyzed at a core laboratory. The largest values measured in the left common carotid artery (LCCA) and the right common carotid artery (RCCA) are averaged in this analysis.
Time frame: Baseline and week 80
Change From Baseline in Height at Weeks 24, 48, and 80
Time frame: Baseline and weeks 24, 48, and 80
Change From Baseline in Weight at Weeks 24, 48, and 80
Time frame: Baseline and weeks 24, 48, and 80
Number of Participants With Change in Tanner Staging From Baseline to Week 80
Pubertal growth and sexual maturity was assessed separately for males and females using the 5 Tanner stages where stage 1 = prepubertal and stage 5 = mature. The number of participants with any change in Tanner Stage from baseline is reported.
Time frame: Baseline and week 80
This study was conducted at 46 centers in 23 countries (Australia, Austria, Belgium, Brazil, Canada, Colombia, Czech Republic, Greece, Hungary, Italy, Malaysia, Netherlands, Norway, Poland, Portugal, Russia, Slovenia, South Africa, Spain, Switzerland, Turkey, United Kingdom, and United States of America).
| Milestone | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Started | 49 | 101 | 13 |
| Received study drug | 49 | 101 | 12 |
| Completed | 48 | 98 | 11 |
| Not completed | 1 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 | 1 |
An adverse event is defined as any untoward medical occurrence in a clinical trial participant, not necessarily having a causal relationship with study treatment. A serious AE is as an AE that met at least 1 of the following criteria: * fatal; * life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * congenital anomaly/birth defect; * other medically important serious event. AEs were graded for severity using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; urgent intervention indicated; Grade 5: Death related to AE.
| Participants | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 36 | 69 | 7 |
| TEAE ≥ Grade 2 | 25 | 56 | 5 |
| TEAE ≥ Grade 3 | 4 | 2 | 2 |
| TEAE ≥ Grade 4 | 0 | 1 | 0 |
| Serious adverse events | 2 | 2 | 2 |
| TEAE leading to discontinuation of evolocumab | 0 | 0 | 0 |
| Fatal adverse events | 0 | 0 | 0 |
For HeFH participants baseline was defined as the baseline value of the parent study 20120123.
| percent change | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HeFH Participants | -36.01 ± 4.28 | -34.96 ± 3.05 |
For HoFH participants baseline was defined as the baseline value in this study (20120124).
| percent change | HoFH: Evolocumab 420 mg QM |
|---|---|
| Percent Change From Baseline to Week 80 in Low-density Lipoprotein Cholesterol (LDL-C) in HoFH Participants | -14.29 (-40.61 to 3.54) |
For HeFH participants baseline was defined as the baseline value of the parent study 20120123.
| percent change | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 80 in Non-HDL-C in HeFH Participants | -32.37 ± 3.96 | -31.95 ± 2.89 |
For HoFH participants baseline was defined as the baseline value in this study (20120124).
| percent change | HoFH: Evolocumab 420 mg QM |
|---|---|
| Percent Change From Baseline to Week 80 in Non-HDL-C in HoFH Participants | -13.03 (-40.68 to 2.69) |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123.
| percent change | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 80 in Apolipoprotein B in HeFH Participants | -27.10 ± 3.32 | -24.15 ± 2.99 |
For HoFH participants baseline was defined as the baseline value in this study (20120124).
| percent change | HoFH: Evolocumab 420 mg QM |
|---|---|
| Percent Change From Baseline to Week 80 in Apolipoprotein B in HoFH Participants | -19.17 (-33.33 to 11.59) |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123.
| percent change | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HeFH Participants | -28.78 ± 3.48 | -28.32 ± 2.47 |
For HoFH participants baseline was defined as the baseline value in this study (20120124).
| percent change | HoFH: Evolocumab 420 mg QM |
|---|---|
| Percent Change From Baseline to Week 80 in Total Cholesterol/HDL-C Ratio in HoFH Participants | 3.71 (-41.17 to 7.57) |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123.
| percent change | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM |
|---|---|---|
| Percent Change From Baseline to Week 80 in Apolipoprotein B / Apolipoprotein A1 Ratio in HeFH Participants | -31.00 ± 3.66 | -29.89 ± 2.80 |
For HoFH participants baseline was defined as the baseline value in this study (20120124).
| percent change | HoFH: Evolocumab 420 mg QM |
|---|---|
| Percent Change From Baseline to Week 80 in Apolipoprotein B/Apolipoprotein A1 Ratio in HoFH Participants | -2.96 (-35.71 to 9.30) |
For HeFH participants baseline was defined as the baseline value of the parent study 20120123.
| mg/dL | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM |
|---|---|---|
| Change From Baseline to Week 80 in LDL-C in HeFH Participants | -67.2 ± 8.2 | -63.1 ± 5.6 |
For HoFH participants baseline was defined as the baseline value in this study (20120124).
| mg/dL | HoFH: Evolocumab 420 mg QM |
|---|---|
| Change From Baseline to Week 80 in LDL-C in HoFH Participants | -36.5 (-180.5 to 16.0) |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
| pmol/L | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Change From Baseline to Week 80 in Estradiol Levels | 131.3 ± 45.3 | 48.2 ± 58.1 | 283.0 ± 130.0 |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
| nmol/L | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Change From Baseline to Week 80 in Testosterone Levels | 5.282 ± 1.567 | 3.230 ± 1.167 | 2.916 ± 0.984 |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
| IU/L | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Change From Baseline to Week 80 in Follicle Stimulating Hormone (FSH) Levels | 1.88 ± 0.90 | 0.60 ± 0.37 | 1.18 ± 0.35 |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
| IU/L | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Change From Baseline to Week 80 in Luteinizing Hormone (LH) Levels | 2.88 ± 1.51 | 1.04 ± 0.95 | 1.76 ± 0.84 |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
| pmol/L | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Change From Baseline to Week 80 in Adenocorticotropic Hormone (ACTH) Levels | 0.78 ± 0.55 | 0.55 ± 0.61 | -0.75 ± 1.79 |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
| μmol/L | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Change From Baseline to Week 80 in Dehydroepiandrosterone Sulfate (DHEA-S) Levels | 1.051 ± 0.222 | 0.956 ± 0.126 | 0.944 ± 0.247 |
For HeFH participants baseline was defined as the baseline value in the parent study 20120123. For HoFH participants baseline was defined as the baseline value in this study (20120124).
| nmol/L | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Change From Baseline to Week 80 in Cortisol Levels | 29.81 ± 28.34 | 51.18 ± 25.19 | 57.26 ± 56.11 |
Liver function tests included alanine aminotransferase (ALT) levels, aspartate aminotransferase (AST) levels and total bilirubin levels.
| Participants | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| ALT or AST > 3 x ULN | 0 | 0 | 0 |
| ALT or AST > 5 x ULN | 0 | 0 | 0 |
| Total bilirubin > 2 x ULN | 0 | 2 | 1 |
The number of participants with levels of creatine kinase greater than 5 times the upper limit of normal (ULN) and greater than 10 times the ULN, measured by the central laboratory.
| Participants | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| CK > 5 x ULN | 0 | 0 | 1 |
| CK > 10 x ULN | 0 | 0 | 0 |
Carotid intima-media thickness measures the thickness of the intima and media, the inner two layers of the carotid artery, and is used to determine the extent of plaque buildup in the walls of the arteries (atherosclerosis) supplying blood to the head. CIMT was measured by ultrasonography and analyzed at a core laboratory. The largest values measured in the left common carotid artery (LCCA) and the right common carotid artery (RCCA) are averaged in this analysis.
| mm | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Change From Baseline to Week 80 in Carotid Intima-media Thickness (cIMT) | -0.019 ± 0.007 | -0.012 ± 0.006 | 0.006 ± 0.032 |
| cm | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Females: Baseline | 158.1 ± 2.3 | 157.9 ± 1.3 | 149.4 ± 7.1 |
| Females: Change at week 24 | 2.8 ± 0.7 | 2.0 ± 0.4 | 1.6 ± 1.1 |
| Females: Change at week 48 | 4.2 ± 1.0 | 2.8 ± 0.5 | 1.4 ± 2.4 |
| Females: Change at week 80 | 4.0 ± 1.7 | 3.4 ± 0.7 | 2.4 ± 3.9 |
| Males: Baseline | 158.2 ± 3.0 | 163.7 ± 1.9 | 158.9 ± 4.8 |
| Males: Change at week 24 | 3.4 ± 0.5 | 3.8 ± 0.5 | 3.8 ± 0.8 |
| Males: Change at week 48 | 6.2 ± 0.8 | 6.2 ± 0.7 | 5.3 ± 1.2 |
| Males: Change at week 80 | 9.3 ± 1.5 | 9.0 ± 1.1 | 9.2 ± 1.6 |
| kg | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Females: Baseline | 52.8 ± 2.9 | 57.0 ± 2.0 | 42.7 ± 1.3 |
| Females: Change at week 24 | 3.3 ± 0.8 | 2.3 ± 0.6 | 3.4 ± 2.1 |
| Females: Change at week 48 | 4.3 ± 1.1 | 3.5 ± 0.7 | 4.7 ± 5.3 |
| Females: Change at week 80 | 5.6 ± 1.3 | 5.2 ± 0.8 | 5.5 ± 4.2 |
| Males: Baseline | 54.1 ± 3.6 | 61.0 ± 3.2 | 51.7 ± 4.9 |
| Males: Change at week 24 | 4.4 ± 0.9 | 4.6 ± 0.7 | 4.6 ± 0.9 |
| Males: Change at week 48 | 6.8 ± 1.3 | 7.4 ± 1.0 | 7.6 ± 1.2 |
| Males: Change at week 80 | 10.9 ± 1.6 | 11.2 ± 1.4 | 10.6 ± 2.3 |
Pubertal growth and sexual maturity was assessed separately for males and females using the 5 Tanner stages where stage 1 = prepubertal and stage 5 = mature. The number of participants with any change in Tanner Stage from baseline is reported.
| Participants | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| Males: Staging by genital size | 13 | 20 | 6 |
| Males: Staging by pubic hair | 14 | 21 | 6 |
| Females: Staging by breast development | 11 | 27 | 1 |
| Females: Staging by pubic hair | 11 | 26 | 1 |
Collected over From first dose of evolocumab in this study up to and including 30 days after the last dose or up to the end of study date, whichever was earlier; up to 80 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | 0/49 (0%) | 2/49 (4.1%) | 27/49 (55.1%) |
| HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | 0/101 (0%) | 2/101 (2%) | 45/101 (44.6%) |
| HoFH: Evolocumab 420 mg QM | 0/13 (0%) | 2/12 (16.7%) | 7/12 (58.3%) |
| Event | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| AppendicitisInfections and infestations | 0/49 | 0/101 | 1/12 |
| Arteriovenous fistula aneurysmInjury, poisoning and procedural complications | 0/49 | 0/101 | 1/12 |
| Appendicitis perforatedInfections and infestations | 1/49 | 0/101 | 0/12 |
| PeritonitisInfections and infestations | 1/49 | 0/101 | 0/12 |
| Wrist fractureInjury, poisoning and procedural complications | 1/49 | 0/101 | 0/12 |
| HeadacheNervous system disorders | 0/49 | 1/101 | 0/12 |
| Anorexia nervosaPsychiatric disorders | 0/49 | 1/101 | 0/12 |
| Event | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/49 | 1/101 | 2/12 |
| NasopharyngitisInfections and infestations | 8/49 | 14/101 | 0/12 |
| Influenza like illnessGeneral disorders | 5/49 | 8/101 | 0/12 |
| PyrexiaGeneral disorders | 5/49 | 1/101 | 0/12 |
| HeadacheNervous system disorders | 4/49 | 9/101 | 1/12 |
| Abdominal pain upperGastrointestinal disorders | 1/49 | 5/101 | 1/12 |
| NauseaGastrointestinal disorders | 0/49 | 1/101 | 1/12 |
| Injection site haemorrhageGeneral disorders | 0/49 | 1/101 | 1/12 |
| InfluenzaInfections and infestations | 0/49 | 3/101 | 1/12 |
| Otitis mediaInfections and infestations | 0/49 | 1/101 | 1/12 |
All enrolled participants
| Age, Continuous(years) | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM | Total |
|---|---|---|---|---|
| Mean | 13.8 ± 2.5 | 14.2 ± 2.4 | 12.4 ± 2.0 | 14.0 ± 2.5 |
| Age, Customized(Participants) | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM | Total |
|---|---|---|---|---|
| 2 - 11 years | 11 | 18 | 6 | 35 |
| 12 - 17 years | 37 | 76 | 7 | 120 |
| 18 - 64 years | 1 | 7 | 0 | 8 |
| Sex: Female, Male(Participants) | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM | Total |
|---|---|---|---|---|
| Female | 24 | 59 | 2 | 85 |
| Male | 25 | 42 | 11 | 78 |
| Ethnicity (NIH/OMB)(Participants) | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 0 | 13 |
| Not Hispanic or Latino | 42 | 95 | 13 | 150 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 | 4 |
| Black or African American | 0 | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 40 | 86 | 9 | 135 |
| Other | 9 | 11 | 2 | 22 |
| Region(Participants) | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM | Total |
|---|---|---|---|---|
| North America | 8 | 12 | 0 | 20 |
| Europe | 33 | 65 | 7 | 105 |
| Latin America | 8 | 18 | 0 | 26 |
| Asia Pacific | 0 | 6 | 6 | 12 |
| Low-density Lipoprotein Cholesterol (LDL-C) Concentration(mg/dL) | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM | Total |
|---|---|---|---|---|
| Mean | 184.0 ± 48.3 | 184.4 ± 45.2 | 426.0 ± 166.4 | 202.2 ± 88.8 |
| Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Concentration(mg/dL) | HeFH (Placebo in Parent Study): Evolocumab 420 mg QM | HeFH (Evolocumab in Parent Study): Evolocumab 420 mg QM | HoFH: Evolocumab 420 mg QM | Total |
|---|---|---|---|---|
| Mean | 201.0 ± 49.3 | 203.4 ± 47.5 | 443.7 ± 170.8 | 220.5 ± 90.2 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Sep 2016 to primary completion in Jun 2021, 56 months.
Results were first posted in Jan 2022, 7 months after primary completion.
Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 56 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evolocumab
Homozygous Familial Hypercholesterolemia →